pre-IPO PHARMA

COMPANY OVERVIEW

Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch™ technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.


LOCATION

  • Sydney, , Australia
  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Vaccines

  • WEBSITE

    https://www.vaxxas.com/home


    CAREER WEBSITE

    https://www.vaxxas.com/about-vaxxas/jobs-at-vaxxas


    SOCIAL MEDIA


    INVESTORS

    brandon-capital healthcare-ventures oneventures the-medical-research-commercialisation-fund


    PRESS RELEASES


    Aug 23, 2023

    Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch


    Jun 18, 2023

    Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products


    Jun 5, 2023

    Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)


    Jun 5, 2023

    Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer


    Mar 30, 2023

    Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)


    For More Press Releases


    Google Analytics Alternative